We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

22 hedge funds and large institutions have $1.49M invested in Biolase, Inc. in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $448K → $1.49M (+$1.04M)

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

16% more funds holding

Funds holding: 19 → 22 (+3)

Holders
22
Holders Change
+3
Holders Change %
+15.79%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$1.3M
2
AIC
AWM Investment Company
New York
+$944K
3
Renaissance Technologies
Renaissance Technologies
New York
+$46.6K
4
VF
Virtu Financial
New York
+$17.4K
5
ZF
Zhang Financial
Michigan
+$10.2K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$81.3K
2
HF
HRT Financial
New York
-$19K
3
TSS
Two Sigma Securities
New York
-$7.24K
4
BlackRock
BlackRock
New York
-$2.92K
5
Morgan Stanley
Morgan Stanley
New York
-$973
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
– -$7.24K -111 Closed
1
2

BIOL Hedge Fund Activity: Q1 2023 in Review

22 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2023, worth a combined $1.49M — up 232% from $448K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BIOL positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 3 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $1.3M. The largest seller was Vanguard Group, cutting an estimated $81.3K.

  • 22 institutional investors held Biolase, Inc. (BIOL) as of Q1 2023, up from 19 in Q4 2022.
  • Funds reported $1.49M of Biolase, Inc. stock for Q1 2023, up 232% quarter-over-quarter.
  • 5 funds opened new Biolase, Inc. positions in Q1 2023 and 2 closed out, a net change of +3 holders.
  • The largest Biolase, Inc. buyer in Q1 2023 was Perkins Capital Management, an estimated $1.3M added.
  • The largest Biolase, Inc. seller in Q1 2023 was Vanguard Group, an estimated $81.3K sold.

Based on aggregated 13F filings for Q1 2023.